Viewing nowCombinationDucanazene Tablet 30/2.5 mg
Fimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
TeraGen Itex Co., Ltd.

MFDS item code 202300131 · Approved 2023.01.06 · Insurance code 698504690
Treatment of essential hypertension inadequately controlled with fimasartan monotherapy
This medication is used as an additional therapy for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with pimasartan potassium. It helps lower blood pressure more effectively in cases where previous blood pressure control has been difficult, thereby reducing the risk of cardiovascular complications. It plays an important role in the treatment of essential hypertension.
The recommended dose of this medicine is 1 tablet once daily, taken with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using fimasartan; however, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is required in elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is required in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min); however, in patients with severe renal impairment (creatinine clearance < 30 mL/min), treatment should be initiated with this medicine containing fimasartan 30 mg. Patients with hepatic impairment No dose adjustment is required in patients with mild hepatic impairment; however, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine in pediatric and adolescent patients aged 18 years or younger have not been established.
This drug can cause serious harm to the fetus and newborn when taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. It should not be used in patients allergic to the main ingredients or similar substances, pregnant or nursing women, patients undergoing renal dialysis, patients with moderate to severe liver impairment, patients with obstructed bile ducts, certain diabetic patients, patients with hereditary lactose intolerance, patients with severe aortic stenosis, or patients in a state of shock. Caution is advised in patients with low blood volume or sodium, patients with impaired kidney function, patients with renovascular hypertension, patients with aortic or mitral valve stenosis, patients with obstructive cardiomyopathy, patients with primary aldosteronism, patients with severe hypotension, elderly patients, and patients hypersensitive to certain dyes. While taking this medication, symptoms such as dizziness, headache, facial or peripheral edema, urination disorders, insomnia, and flushing may occur, so patients should monitor their symptoms closely. Patients with hypotension or electrolyte imbalance may experience excessively low blood pressure at the beginning of treatment, and proper measures should be taken immediately if hypotension occurs. This drug may increase serum potassium levels, so patients with heart failure or kidney disorders should regularly test potassium levels through blood tests. Patients with renal artery stenosis should be cautious as kidney function may deteriorate upon taking this medication. As with other antihypertensive agents, patients with heart or cerebrovascular diseases should be cautious of aggravation due to excessive blood pressure lowering. While taking this medication, drowsiness or dizziness may occur, so caution is advised when driving or operating dangerous machinery. Pregnant or nursing women should avoid taking this medication, especially during pregnancy, as it may pose serious risks to the fetus, and it should be discussed with a doctor. The safety and efficacy in children or adolescents under 18 years of age have not been established, so use is not recommended. Generally, elderly patients do not require dose adjustments; however, some elderly patients may be more sensitive to the medication, so caution is necessary. This medication should not be used in patients with moderate to severe liver dysfunction. In case of overdose, hypotension, or irregular heartbeats may occur, and immediate contact with a medical institution for appropriate treatment is required. This medication should be stored out of reach of children, and transferring it to another container may cause deterioration in quality or accidents, so caution is advised.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container that can block light, ideally at room temperature between 1 and 30 degrees Celsius. This helps maintain the drug's effectiveness and prevent deterioration.
White rectangular film-coated tablet with rounded corners
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
TeraGen Itex Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.